The Aging Liver
- 1 January 1998
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 34 (5) , 359-373
- https://doi.org/10.2165/00003088-199834050-00003
Abstract
A change in drug clearance with age is considered an important factor in determining the high prevalence of adverse drug reactions associated with prescribing medications for the elderly. Despite this, no general principles have been available to guide drug administration in the elderly, although a substantial body of clearance and metabolism data has been generated in humans and experimental animals. A review of age-related change in drug clearances established that patterns of change are not simply explained in terms of hepatic blood flow, hepatic mass and protein binding changes. In particular, the maintained clearance of drugs subject to conjugation processes while oxygen-dependent metabolism declines, and all in vitro tests of enzyme function have been normal, requires new explanations. Reduction in hepatic oxygen diffusion as part of a general change in hepatocyte surface membrane permeability and conformation does provide one explanation for the paradoxical patterns of drug metabolism, and increased hepatocyte volume would also modify oxygen diffusion path lengths (the ‘oxygen diffusion barrier’ hypothesis). The reduction in clearances of high extraction drugs does correlate with observed reduction in hepatic perfusion. Dosage guidelines emerge from these considerations. The dosage of high clearance drugs should be reduced by approximately 40% in the elderly while the dosage of low clearance drugs should be reduced by approximately 30%, unless the compound is principally subject to conjugation mechanisms. If the hepatocyte diffusion barrier hypothesis is substantiated, this concept may lead to therapeutic (preventative and/or restorative) approaches to increased hepatocyte oxygenation in the elderly. This may lead to approaches for modification of the aging process in the liver.Keywords
This publication has 79 references indexed in Scilit:
- Clinical Pharmacokinetic Considerations in the ElderlyClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver DiseaseClinical Pharmacokinetics, 1995
- Epidemiology of Adverse Drug Events in the Nursing Home SettingDrugs & Aging, 1995
- Clinical Pharmacokinetics in Patients with Liver DiseaseClinical Pharmacokinetics, 1991
- Hepatic Drug Metabolism and AgingClinical Pharmacokinetics, 1990
- Plasma Protein Binding of Drugs in the ElderlyClinical Pharmacokinetics, 1987
- Influence of age-related changes in rodent liver morphology and physiology on drug metabolism — A reviewMechanisms of Ageing and Development, 1984
- Comparative pharmacokinetics of caffeine in young and elderly menJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in ManClinical Pharmacokinetics, 1981
- Propranolol Disposition in Chronic Liver DiseaseClinical Pharmacokinetics, 1976